Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

Sponsor
Messoud Ashina, MD
Study ID
NCT05214001
Phase
PHASE4
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Almotriptan 12.5 Mg Oral Tablet — DRUG
    Treatment for an acute, moderate to severe migraine attack
  • Ubrogepant 50Mg Tab — DRUG
    Treatment for an acute, moderate to severe migraine attack

Study Details

In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.

Key Dates

Start date
Jun 30, 2022
Status verified
May 2025
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024

Study Design

Enrollment
8 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Almotriptan
    12.5 mg almotriptan taken orally once
  • Active Comparator: Ubrogepant
    50 mg ubrogepant taken orally once

Primary Outcome Measure

Pain freedom at 2 hours [ Time Frame: 2 hours after initial dose ]

Related Studies